Photosensitizer with high ROS (reactive oxygen species) generation efficiency and antitumor activity
By synthesizing the water-soluble bipyridine iridium complex Ir-OH, the concentration of ROS in tumor cells is increased, causing lysosomal damage. This solves the problem of insufficient ROS generation efficiency in existing photodynamic therapy, achieving highly efficient anti-tumor activity and minimally invasive treatment.
Patent Information
- Application Number
- CN202410954098.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-17
- Publication Date
- 2024-11-26
AI Technical Summary
Existing photosensitizers for photodynamic therapy are not efficient enough in increasing ROS concentration and antitumor activity in tumor cells, making it difficult to meet clinical needs.
A water-soluble bipyridine-iridium complex, Ir-OH, was synthesized. By coordinating bipyridine with iridium, a photosensitizer with high ROS generation efficiency, Ir-OH, was prepared. Under light irradiation, it increases the ROS concentration in tumor cells, causing lysosomal damage and inducing tumor cell apoptosis or necrosis.
Ir-OH exhibits high ROS production efficiency and good anti-tumor activity, can specifically kill tumor cells, has low toxicity and does not cause significant damage to normal tissues, and has significant tumor-suppressing effects and is minimally invasive.
Smart Images

Figure CN119019462A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of analysis and detection, in particular to a photosensitizer with high ROS generation efficiency and anti-tumor activity. Background Art
[0002] Cancer has always been one of the major diseases threatening human health. According to the latest statistics, about one in six deaths is caused by cancer. Researchers have been committed to developing and screening more efficient anticancer drugs and treatment strategies. At present, although surgery, radiotherapy and chemotherapy can prolong the life cycle of patients to a certain extent, it is still difficult to meet the urgent clinical needs. Photodynamic therapy (PDT), as an emerging treatment method, can specifically kill tumor cells while ensuring that normal tissues are not damaged due to its many advantages such as low toxicity, good targeting, and minimally invasiveness. It is gradually becoming a research hotspot in the field of cancer treatment and has shown great potential in the treatment of various types of tumors. Photodynamic therapy has now become a promising treatment method for a variety of diseases including cancer.
[0003] Photosensitizer is one of the important factors affecting the effect of photodynamic therapy. It can produce photochemical reactions under light and destroy the structure and function of tumor cells. Commonly used photosensitizers include metal complexes, hematoporphyrin derivatives and porphin compounds. Among them, metal complexes have attracted much attention in photodynamic therapy due to their efficient reactive oxygen generation ability and excellent photostability. In particular, the heavy atom iridium in the metal iridium complex can significantly enhance the spin-inductive coupling effect, thereby improving the inter-gap crossing efficiency from the excited singlet state to the excited triplet state. When the metal iridium complex reaches the excited triplet state, part of the energy is released as phosphorescence, while the other part of the energy is transferred to the ground state oxygen through energy transfer or charge transfer, thereby generating reactive oxygen. This characteristic makes metal iridium complexes show broad application prospects in related fields, especially in anti-tumor therapy.
[0004] The present invention utilizes the high ROS generation efficiency of metal iridium complexes, the good biological activity and water solubility of bipyridine, and synthesizes the water-soluble bipyridine metal iridium complex Ir-OH by coordinating bipyridine with metal iridium. The photophysical properties and ROS generation efficiency of the complex as well as its application in anti-tumor activity are also explored. Summary of the invention
[0005] 1. Technical issues to be resolved
[0006] In view of the shortcomings of the prior art, the present invention provides a bipyridine metal iridium complex photosensitizer Ir-OH with high ROS generation efficiency and anti-tumor activity and a preparation method thereof. The photosensitizer can increase the ROS concentration in tumor cells under light conditions to cause lysosomal damage, reveal the correlation between the photosensitizer and the lysosomal apoptosis pathway, achieve lysosomal apoptosis and cause tumor cell apoptosis or necrosis, and further explore the effect of the photosensitizer on mouse tumor growth under light conditions through in vivo imaging.
[0007] (II) Technical solution
[0008] One of the purposes of the present invention is to provide a photosensitizer Ir-OH with high ROS generation efficiency and anti-tumor activity and a preparation method thereof. The photosensitizer is prepared by coordinating bipyridine with metal iridium to synthesize a water-soluble bipyridine metal iridium complex.
[0009] The synthesis of the photosensitizer uses chlorophenylpyridine iridium complex as the matrix, and 4,4'-dihydroxymethyl-2,2-bipyridine is modified on the matrix to synthesize Ir-OH. The specific synthesis route is as follows:
[0010] (1) The iridium chlorophenylpyridine complex and 4,4'-dihydroxymethyl-2,2-bipyridine were fully dissolved in a dichloromethane / methanol mixed solution, and then the temperature was gradually raised to 55° C. in an oil bath and reacted for 12 hours.
[0011] (2) After the reaction is completed, the mixture is naturally cooled to room temperature, and then an appropriate amount of ammonium hexafluorophosphate is added and stirred for half an hour. After cooling, the mixture is separated and purified by column chromatography to obtain a yellow solid, which is Ir-OH.
[0012] In a further technical solution, the volume ratio of the methyl chloride / methanol mixed solution in step (1) is 1:1.
[0013] The second purpose of the present invention is to utilize the characteristics of the photosensitizer Ir-OH to treat tumors by photodynamic therapy (PDT). 1 The generation efficiency of O2 and reactive oxygen species (ROS) is a key factor in evaluating the effect of PDT. 1 The O2 and ROS production efficiency were used to preliminarily evaluate the feasibility of photosensitizers for PDT.
[0014] Ir-OH was compared with the commercial photosensitizer chlorin e6 (Ce6), using 9,10-anthracenediyl-bis(methylene)dicarboxylic acid (ABDA) and 2,7-dichlorodihydrofluorescein diacetate (DCFH) as singlet oxygen ( 1 O2) and reactive oxygen species (ROS) detection reagents.
[0015] In a further technical solution, when ABDA captures1 When O2 is present, the absorption intensity of its maximum absorption wavelength at 378 nm decreases. Therefore, we can determine the generation of Ir-OH by evaluating the photobleaching degree of ABDA. 1 O2 capabilities.
[0016] In a further technical solution, DCFH itself has no fluorescence, but when it comes into contact with ROS, DCFH will be oxidized by ROS into a strong fluorescent fluorescein (DCF). DCF can emit green fluorescence in the visible light region, and the intensity of the fluorescence signal is positively correlated with the concentration of ROS. Therefore, by measuring the intensity of the fluorescence signal emitted by DCF, the level of ROS production can be indirectly reflected.
[0017] The test results show that within 300s of illumination, Ir-OH exhibits a stronger 1 O2 and ROS production rates.
[0018] The third purpose of the present invention is to determine that the photosensitizer is localized in lysosomes through co-localization experiments, and can increase the ROS concentration in tumor cells under light conditions to cause lysosomal damage, thereby developing the application of photosensitizers at the cellular level.
[0019] The fourth purpose of the present invention is the application of the photosensitizer in vivo, which is specifically manifested as: it shows a good in vivo tumor inhibition effect on the 4T1 mouse tumor model in vivo, and has no obvious toxic side effects on the main organ tissues of the mouse.
[0020] The working principle of the photosensitizer of the present invention is as follows: by utilizing the high ROS generation efficiency of metal iridium complexes, the good biological activity and water solubility of bipyridine, the water-soluble bipyridine metal iridium complex Ir-OH is synthesized by coordinating bipyridine with metal iridium. Under light conditions, Ir-OH increases the ROS concentration in tumor cells, causing lysosomal damage, triggering the lysosomal apoptosis pathway, and then causing tumor cell apoptosis or necrosis. Finally, the anti-tumor activity of Ir-OH in 4T1 tumor model mice was tested, and staining and imaging observations of tumor and other tissue sections were performed.
[0021] (III) Beneficial effects
[0022] The present invention provides a photosensitizer with high ROS generation efficiency and anti-tumor activity. Compared with the prior art, it has the following beneficial effects:
[0023] (1) The photosensitizer with high ROS generation efficiency and anti-tumor activity, wherein the photosensitizer Ir-OH is a bipyridine metal iridium complex, wherein the metal iridium has a high ROS generation efficiency and can increase the ROS concentration in tumor cells. At the same time, bipyridine has good biological activity and water solubility. After it is combined with the metal iridium, it can improve the biocompatibility of the photosensitizer and make it easier to be taken up.
[0024] (2) The photosensitizer has high ROS generation efficiency and anti-tumor activity. The preparation method of the photosensitizer Ir-OH provided by the photosensitizer is simple, the raw materials are easily available, and it is easy to repeat.
[0025] (3) This photosensitizer with high ROS production efficiency and anti-tumor activity is used to treat tumors through photodynamic therapy (PDT). With its many advantages such as low toxicity, good targeting, and minimal invasiveness, it can specifically kill tumor cells while ensuring that normal tissues are not damaged. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 Schematic diagram of the synthesis of the photosensitizer of the present invention;
[0027] Figure 2 This is the hydrogen spectrum of the photosensitizer synthesized in Example 1 of the present invention;
[0028] Figure 3 This is the carbon spectrum of the photosensitizer synthesized in Example 1 of the present invention;
[0029] Figure 4 This is the mass spectrum of the photosensitizer synthesized in Example 1 of the present invention;
[0030] Figure 5 The UV-visible absorption spectrum and fluorescence spectrum of Ir-OH in Example 2 of the present invention;
[0031] Figure 6 is the Ir-OH in Example 3 of the present invention 1 O2 and ROS production rate determination diagram: (a) relative change of absorbance of ABDA under white light exposure at different time, (b) relative change of absorbance of DCFH under white light exposure at different time;
[0032] Figure 7 The MTT method in Example 4 of the present invention measures the survival rates of Hep G2 and 3T3 cells under dark conditions with different concentrations of Ir-OH;
[0033] Figure 8 The MTT method in Example 5 of the present invention is used to measure the survival rate of Hep G2 cells under light conditions with a working concentration of 10 μM Ce6 and Ir-OH over time;
[0034] Fig. 9 This is a confocal image of the co-localization experiment of Ir-OH in cells in Example 6 of the present invention;
[0035] Fig.10 This is a confocal image of the Ir-OH lysosome damage experiment in Example 7 of the present invention;
[0036] Fig.11 This is a confocal image of the ROS generation experiment in Ir-OH cells in Example 8 of the present invention;
[0037] Fig.12 This is a confocal image of the experiment to explore the lysosomal damage process of Ir-OH in cells in Example 9 of the present invention;
[0038] Fig.13 The experimental figures of the anti-tumor activity experimental study in Example 10 of the present invention, (a) Mouse weight. (b) Changes in tumor volume. (c) Tumor weight after 16 days of treatment in each group by intratumoral injection of PBS (control group), commercial photosensitizer Ce6 (control group) and Ir-OH (experimental group). (d) Pictures of mouse tumors after 16 days of treatment in each group;
[0039] Fig.14 The figure is a histological observation of H&E pathological section staining of the main organs of heart, liver, spleen, lung and kidney in each group after 16 days of treatment in Example 11 of the present invention;
[0040] Fig.15 These are pictures of H&E pathological section staining and TUNEL staining histological observation of tumor tissues in each group after 16 days of treatment in Example 11 of the present invention. DETAILED DESCRIPTION
[0041] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0042] See also Figure 1-15 The embodiments of the present invention provide eleven technical solutions: a photosensitizer with high ROS production efficiency and anti-tumor activity, and the raw materials in the following embodiments are described as follows:
[0043] Methanol, ethanol, dimethyl sulfoxide, acetonitrile, N,N-dimethylformamide, tetrahydrofuran, ethyl acetate, dichloromethane, toluene, and acridine orange (AO) were purchased from Sinopharm Chemical Reagent Co., Ltd.
[0044] 2,2-Bipyridine, ammonium hexafluorophosphate, chlorophenylpyridine, and methazolyl blue (MTT) were purchased from Shanghai Aladdin Biochemical Technology Co., Ltd.
[0045] DCFH and ABDA were purchased from Shanghai Bio-Technology Co., Ltd.
[0046] Cell culture medium DMEM, fetal bovine serum (FBS), trypsin cell digestion solution, lysosome localization dye, mitochondrial localization dye, and cell nucleus localization dye were all purchased from Sigma.
[0047] Example 1: Preparation of photosensitizer Ir-OH
[0048] 1. Synthesis of Ir-OH
[0049] Ir-OH was synthesized by using chlorophenylpyridine iridium complex as the matrix and modifying 4,4'-dihydroxymethyl-2,2-bipyridine on the matrix.
[0050] The specific synthesis steps are as follows: 0.107 g (1 mmol) of chlorophenylpyridine iridium complex and 0.108 g (5 mmol) of 4,4'-dihydroxymethyl-2,2-bipyridine, as well as 50 mL of a mixed solution of dichloromethane / methanol (volume ratio 1:1) are added at once into a 250 mL round-bottom flask to fully dissolve them, and then the temperature is gradually raised to 55° C. in an oil bath, and a condenser is connected to condensed water for condensation, and the reaction is performed for 12 hours. After the reaction is completed, the mixture is naturally cooled to room temperature, and then an appropriate amount of ammonium hexafluorophosphate is added and stirring is continued for half an hour. After cooling, the mixture is separated and purified by column chromatography to obtain a yellow solid, namely Ir-OH. 1 H NMR (400MHz, DMSO-d6) δ8.69 (s, 2H), 8.22 (d, J = 8.1Hz, 2H), 7.93-7.84 (m, 6H), 7.62-7.54 (m, 4H), 7.16-7.08 (m, 2H) ,7.02-6.93(m,2H),6.86(td,J=7.4,1.3Hz,2H),6.16(d,J=6.3Hz,2H),5.71(t,J=5.5Hz,2H),4.71(d,J=5.4Hz,4H). 13 C NMR (101MHz, DMSO-D6) δ167.43,156.51,155.61,151.19,149.90,149.29,144.36,139.25,131.65,130. 77,126.18,125.61,124.41,122.73,122.25,120.55,61.83,56.56,19.09.HR-MS(m / z,ESI)Calculated for(C 34H 28 IrN4O2)m / z=717.1842[M].Found m / z=717.1814.
[0051] pass Figure 2-Figure 4 The characterization results of hydrogen spectrum, carbon spectrum and mass spectrum can prove the successful synthesis of Ir-OH.
[0052] Example 2: Study on the Photophysical Properties of Ir-OH
[0053] 1. UV-Vis absorption and fluorescence spectra of Ir-OH
[0054] Firstly, the UV-visible absorption spectrum of Ir-OH in PBS solution was measured. A double-pass cuvette with a size of 1 cm was used, 2 mL of a solution with a working concentration of 10 μM was added, and the UV-visible absorption spectrum was obtained by measuring with a UV-visible spectrophotometer.
[0055] Secondly, the fluorescence emission spectrum of Ir-OH was measured. A four-way cuvette with a size of 1 cm was used, 2 mL of a solution with a working concentration of 10 μM was added, and then its fluorescence emission spectrum was obtained by measurement. In order to be consistent with subsequent cell experiments, a 405 nm wavelength laser was used to excite Ir-OH, the emission wavelength range was set to 450-800 nm, the slit width was set to 10 nm, and the excitation voltage was set to 400 V. We found through UV-visible absorption spectroscopy that the absorption peak of Ir-OH is around 310 nm, and the fluorescence emission spectrum of Ir-OH is between 500-800 nm, with the maximum emission wavelength at around 620 nm. The experimental results are as follows Figure 5 As shown in (a) and (b).
[0056] 2. Study on the solvent effect of Ir-OH
[0057] Ir-OH was placed in solvents of different polarities to ensure that the concentration of Ir-OH in the solvents was 10 μM, and the changes in the UV-visible absorption spectrum and fluorescence emission spectrum of Ir-OH in the solvents were measured. Figure 5 As shown in (c), at room temperature, the UV-visible absorption spectrum of Ir-OH does not change in solvents of different polarities, indicating that Ir-OH has no obvious solvation effect and is a polarity-insensitive molecule, which further proves that Ir-OH is a very stable complex. Figure 5As shown in (d), under room temperature, by using a 405nm laser light source for excitation, it can be seen that in different solvents, Ir-OH shows a stronger fluorescence intensity than in water. Although the fluorescence emission spectrum shows different degrees of blue shift with the change of solvent polarity, it does not show polarity dependence, which further supports the results of UV-visible absorption spectrum. Therefore, Ir-OH is a molecule with no obvious solvent effect and is relatively stable.
[0058] Example 3. Ir-OH 1 O2 and ROS production rate determination
[0059] Singlet oxygen ( 1 O2) and reactive oxygen species (ROS) are key factors in the PDT effect. 1 The O2 and ROS production efficiency were used to preliminarily evaluate the feasibility of photosensitizers for PDT. Ir-OH was compared with the commercial photosensitizer dihydrochlorin e6 (Ce6), and 9,10-anthracenediyl-bis(methylene)dicarboxylic acid (ABDA) and 2,7-dichlorodihydrofluorescein diacetate (DCFH) were used as singlet oxygen ( 1 O2) and reactive oxygen species (ROS) detection reagents.
[0060] When ABDA captures 1 When O2 is present, the absorption intensity of its maximum absorption wavelength at 378 nm decreases. Therefore, we can determine the generation of Ir-OH by evaluating the photobleaching degree of ABDA. 1 O2's capabilities.
[0061] The specific experimental steps are as follows: using a 1 cm double-pass cuvette, first add 2 mL of PBS solution containing 10 μM Ir-OH, then add ABDA solution to ensure that the final working concentration of ABDA is 40 μM. Then use LED light (100 mW / cm 2 ) was continuously irradiated, and the UV-visible absorption spectrum was measured every 30 seconds for a duration of 5 minutes, and the change of its absorbance at 378 nm was recorded.
[0062] DCFH itself has no fluorescence, but when it comes into contact with ROS, DCFH will be oxidized by ROS into a strong fluorescent fluorescein (DCF). DCF can emit green fluorescence in the visible light region, and the intensity of the fluorescence signal is positively correlated with the concentration of ROS. Therefore, by measuring the intensity of the fluorescence signal emitted by DCF, the level of ROS production can be indirectly reflected.
[0063] The specific experimental steps are as follows: using a 1 cm four-way cuvette, first add 2 mL of PBS solution containing 10 μM Ir-OH, then add DCFH solution to ensure that the final working concentration of DCFH is 40 μM. Then use LED light (100 mW / cm 2 ) was continuously irradiated, and the fluorescence spectrum was measured every 30 seconds for a duration of 5 minutes. The changes in the fluorescence spectrum at 527 nm were recorded.
[0064] like Figure 6 The test results show that within 300s of illumination, Ir-OH exhibits a stronger 1 O2 and ROS production rates.
[0065] Example 4: Effect of Ir-OH on Cell Viability
[0066] Before performing cell fluorescence imaging of Ir-OH, it is necessary to ensure that Ir-OH has no effect on normal cell growth and proliferation, which is the most basic requirement for molecules used for cell imaging. Therefore, the cytotoxicity of Ir-OH under dark conditions was evaluated.
[0067] The experimental results are as follows Figure 7 As shown in the figure, after incubating Ir-OH with cells in dark conditions for 12 hours, within the concentration range of 10 μM, the survival rates of tumor cells Hep G2 and normal cells 3T3 were both above 85%, indicating that Ir-OH has low dark cell toxicity and will not affect the normal physiological functions of cells. Therefore, in subsequent experiments, we chose to use Ir-OH with a working concentration of 10 μM to cultivate cells, which is more conducive to subsequent experiments.
[0068] Example 5: Photocytotoxicity of Ir-OH
[0069] From above Figure 7 It can be seen that for Ir-OH, under dark conditions, when the concentration reaches 10μM, Hep G2 cells have a survival rate of more than 85%, which indicates that Ir-OH exhibits low dark toxicity to Hep G2 cells. Therefore, 10μM was selected as the working concentration of Ir-OH for the photocytotoxicity experiment on Hep G2 cells, and compared with the commercial photosensitizer Ce6 to explore the photocytotoxicity of Ir-OH cells with increasing illumination time.
[0070] The experimental results are as follows Figure 8As shown in the figure, Ir-OH exhibited obvious photocytotoxicity after 3 hours of illumination compared to 0 hours. As time went on, the photocytotoxicity continued to increase, and reached a cell survival rate of only about 10% at 24 hours. However, when comparing the photocytotoxicity of commercial photosensitizer Ce6 to Hep G2 cells, it was found that under the same treatment conditions, the photocytotoxicity of Ir-OH was significantly higher than that of commercial photosensitizer Ce6, which means that Ir-OH may have greater potential for application in PDT.
[0071] Example 6: Ir-OH co-localization experiment in cells
[0072] After evaluating the phototoxicity and dark toxicity of Ir-OH, it is also crucial to clarify the distribution of Ir-OH in cells. The method commonly used in experiments is to co-localize with commercial dyes in cells to determine the location of Ir-OH in cells. From the in vitro data above, it can be seen that a wavelength of 405nm should be selected as the optimal excitation wavelength for Ir-OH, and the lysosomal deep red commercial dye Lyso-Tracker Deep Red, the mitochondrial deep red commercial dye Mito-Tracker Deep Red, and the nuclear commercial dye Hoechst33342 were selected for co-localization experiments.
[0073] The specific steps are as follows: First, remove the original culture medium in the culture dish and wash it several times with PBS buffer solution. Then, we add 1mL of serum-free culture medium and Ir-OH, and ensure that the working concentration of Ir-OH is 10μM, and incubate for 30 minutes. After the incubation, remove the culture medium containing Ir-OH and wash it three times with PBS buffer solution again to ensure that Ir-OH that has not entered the cells is completely removed. Then, add Lyso-TrackerDeep Red, a lysosomal deep red commercial dye, to the serum-free culture medium, adjust its working concentration to 1μM, and incubate for 20 minutes for confocal imaging observation.
[0074] During the imaging process, we used 405nm and 647nm lasers to excite Ir-OH and Lyso-Tracker Deep Red, the commercial dye for lysosomes, respectively, and their corresponding emission wavelength ranges were 620-650nm and 650-690nm, respectively. Mitochondrial deep red commercial dye Mito-Tracker Deep Red and nuclear commercial dye Hoechst 33342 were excited at 644nm and 405nm wavelengths, respectively, and their corresponding emission wavelength collection ranges were 680-710nm and 400-480nm.
[0075] The experimental results are as follows Fig. 9As shown in the figure, the fluorescence signal of Ir-OH overlaps highly with the fluorescence signal of Lyso-Tracker Deep Red, a commercial dye for lysosomes. Further analysis by confocal software shows that the Person's correlation coefficient is as high as 0.77. In contrast, the fluorescence signal overlap between Ir-OH and mitochondria and nuclei is lower, with Person's correlation coefficients of 0.44 and 0.34, respectively. This experimental result clearly shows that Ir-OH can specifically target lysosomes in cells.
[0076] Example 7: Ir-OH lysosomal damage experiment
[0077] Lysosomes are important acidic organelles that are essential for a variety of cellular processes, including post-translational protein maturation, receptor degradation, apoptosis, autophagy, and the release of extracellular enzymes. In order to further explore the functional state of lysosomes, researchers often use acridine orange (AO), a fluorescent dye. Only lysosomes in cells can hydrolyze AO into two fluorescent dyes. In intact lysosomes, AO binds to protons in an acidic environment to form protonated oligomers that emit red fluorescence. In the cytoplasm, AO appears as a deprotonated monomer that emits green fluorescence. When lysosomes are damaged or the intracellular acid-base balance is disturbed, the pH value will rise, resulting in reduced binding of AO to protons and quenching of fluorescence. This change in fluorescence properties provides us with a powerful tool to observe the state of lysosomes.
[0078] To study the effect of Ir-OH on lysosomes, we first incubated Hep G2 cells with Ir-OH (10 μM) for 0.5 h and then used LED light (100 mW / cm 2 ) for 5 min every 3 hours, and AO (5 mM) was added for staining after 0, 3, and 6 hours, and fluorescence imaging was performed using a confocal microscope. Fig.10 The results showed that at 3 hours, the red fluorescence of the lysosomes in the cells was significantly weakened compared to 0 hours, especially after 6 hours, when only weak red fluorescence was emitted from the lysosomes, indicating that lysosomal damage was particularly obvious. This result strongly proves that Ir-OH can target lysosomes and cause lysosomal damage.
[0079] Example 8: Ir-OH intracellular ROS production experiment
[0080] Since Ir-OH exhibits high ROS production efficiency in vitro, it is also crucial to detect the ROS production efficiency of Ir-OH in cells, so 2,7-dichlorofluorescein (DCFH-DA) was selected as a fluorescent probe to monitor the ROS production efficiency in cells. This probe can react chemically with ROS and convert into 2,7-dichlorofluorescein (DCF) that emits green fluorescence, providing us with an intuitive and effective method to evaluate the ROS production efficiency of Hep G2 cells after Ir-OH treatment.
[0081] DCFH-DA itself has no fluorescent properties, but it can penetrate the cell membrane and enter the cell. Once inside the cell, DCFH-DA will be hydrolyzed by the esterase in the cell and converted into DCFH. It is worth noting that DCFH cannot cross the cell membrane again, so it will stay in the cell. When the level of ROS in the cell increases, they will react with DCFH to produce DCF that emits green fluorescence. By observing the changes in the fluorescence intensity of DCF, we can effectively evaluate the generation of ROS by Ir-OH in the cell.
[0082] Two groups of experiments were set up. The control group was incubated with 10 μM Ir-OH and Hep G2 cells for 0.5 h without light exposure. The experimental group was incubated with 10 μM Ir-OH and Hep G2 cells for 0.5 h but under the LED light (100 mW / cm 2 ) were used for confocal microscopy imaging. Fig.11 As shown, the control group showed weak DCF green fluorescence within 0-40 minutes, which may be due to the ROS generated by the cells themselves or the ROS generated by some Ir-OH under the 488nm wavelength laser irradiation during the imaging process. However, compared with the control group, the experimental group gradually produced strong DCF green fluorescence within 0-40 minutes, and the fluorescence intensity was much higher than that of the control group. The confocal imaging experimental results can prove that Ir-OH can indeed generate ROS in cells.
[0083] Example 9: Experimental study on the lysosomal damage process of Ir-OH in cells
[0084] Lysosomes are essential organelles in eukaryotic cells, and their structural integrity and functional stability play a decisive role in the normal operation of cells. However, the molecular mechanisms regulating these behaviors are not well understood. Therefore, tracking the changes in lysosomal morphology may help to further study the mechanism of cell death. Therefore, we tracked lysosomes in real time by monitoring the fluorescence emission of Ir-OH in Hep G2 cells using confocal microscopy.
[0085] Specifically, Ir-OH (10 μM) was co-incubated with Hep G2 cells in the dark for 0.5 h, and then the experimental group was illuminated with LED light (100 mW / cm 2 ) were continuously irradiated, while the control group was not exposed to light, and then confocal microscopy imaging was performed. Fig.12 As shown in the figure, in the control group, Ir-OH was normally located in the lysosome. As time went on, the fluorescence intensity and fluorescence position remained basically unchanged, and there was no significant change in the bright field cells. However, for the experimental group, as the illumination time increased, the lysosomes showed normal distribution at 0 min. Ir-OH could effectively mark the lysosomes in Hep G2 cells. As the illumination time increased, the normal lysosomes collapsed, and the fluorescence originally marked the lysosomes gradually dispersed into the cytoplasm. The cell bright field could clearly see that as time went on, apoptotic bodies gradually appeared in the cells. In cells treated with Ir-OH, fragmented lysosomes tended to be located around the nucleus.
[0086] Example 10: Experimental study on anti-tumor activity
[0087] Ir-OH exhibited good ROS production efficiency in vitro and in Hep G2 cells, so a mouse tumor model was further used to evaluate the photodynamic antitumor therapeutic effect of Ir-OH.
[0088] After continuous light treatment, the changes in mouse body weight and tumor volume were continuously monitored. The experimental results are as follows: Fig.13 As shown in (a). As time passes after administration, the weight of mice generally increases. The weight changes of mice in the commercial photosensitizer Ce6 and Ir-OH treatment groups and the PBS control group are very different, which indicates that commercial photosensitizer Ce6 and Ir-OH do not cause obvious toxic side effects on mice. However, as the treatment time passes, Fig.13 As shown in (b), the difference in tumor volume between the three treatment groups is getting bigger and bigger. Comparing the commercial photosensitizer Ce6 treatment group and the PBS control group, it is found that in the early 0-6 days, the tumor growth rates of the two are similar, but as the treatment time increases, the tumor growth rate of the commercial photosensitizer Ce6 treatment group is inhibited, and the difference in tumor volume size with the PBS control group also increases. In the Ir-OH treatment group, the tumor growth rate is inhibited after the drug administration and light treatment. The tumor growth rate is significantly slower than that of the commercial photosensitizer Ce6 treatment group and the PBS control group. This is also consistent with the in vitro cytotoxicity results. Compared with the PBS control group and the commercial photosensitizer Ce6, the photodynamic antitumor activity of Ir-OH is significantly enhanced. After 16 days of antitumor activity treatment, all experimental mice were euthanized, and their main organs, heart, liver, spleen, lung, kidney and tumor tissues were removed, and the tumor tissues were weighed, as shown in the figure. Fig.13As shown in (c), the tumor weight of mice in the commercial photosensitizer Ce6 treatment group was lower than that in the PBS control group, while the tumor weight of mice in the Ir-OH treatment group was lower than that in the PBS treatment group and the commercial photosensitizer Ce6 treatment group. The difference in tumor tissue weights among the three treatment groups after 16 days of treatment also confirmed that Ir-OH has a good in vivo photodynamic anti-tumor activity therapeutic effect. Fig.13 (d) shows the tumor sizes of mice in the PBS control group, commercial photosensitizer Ce6 treatment group, and Ir-OH treatment group after 16 days of PDT treatment. It can be found that the tumors of mice in the Ir-OH treatment group are smaller than those in the other two groups, which more intuitively demonstrates the anti-tumor therapeutic effect of Ir-OH.
[0089] Example 11: Histological observation experiment
[0090] In order to further understand the effects of Ir-OH on mouse tumors and their main organs during the anti-tumor activity. We also explored the damage to the main normal tissues and tumor tissues of mice and the apoptosis of tumor cells in the PBS-treated group, the commercial photosensitizer Ce6-treated group, and the Ir-OH-treated group after PDT. After 16 days of anti-tumor treatment, we collected the heart, liver, spleen, lung, kidney, tumor and other tissues of the mice and performed H&E pathological section staining. After H&E staining, the originally transparent tissue sections can clearly show the tissue structure, type and cell level to observe the effect of treatment on the tissue. At the same time, we also performed TUNEL staining on the tumor tissues of mice to further understand the apoptosis of tumor cells during the PDT process.
[0091] The experimental results are as follows Fig.14 As shown, the cell morphology of the mouse heart, liver, spleen, lung, kidney, tumor and other organs in the PBS control group remained intact without any obvious histopathological damage. By comparing the tumor tissue sections of the commercial photosensitizer Ce6 treatment group and the Ir-OH treatment group with the PBS control group, it was found that the commercial photosensitizer Ce6 treatment group and the Ir-OH treatment group caused tissue damage to the tumor tissue after illumination, while no tissue damage was seen in other organs. This indicates that the commercial photosensitizer Ce6 treatment group and the Ir-OH treatment group do not affect normal tissues, but are limited to tumor tissues and cause selective damage. From the tumor tissue stained with TUNEL Fig.15 It can be seen that compared with the PBS treatment group and the photosensitizer Ce6 treatment group, the Ir-OH treatment group showed more cell apoptosis (blue in the figure represents normal cells and red represents apoptotic cells).
[0092] In summary, the photosensitizer of the present invention is a metal complex of bipyridine and metal iridium, which has high ROS generation efficiency, excellent anti-tumor activity and biocompatibility. When the photosensitizer enters tumor cells, it can cause lysosomal damage, thereby damaging tumor cells. Under light conditions, the photosensitizer can inhibit the growth of mouse tumors through photodynamic therapy (PDT), which helps to provide certain guidance and reference for subsequent PDT clinical research.
[0093] Meanwhile, the contents not described in detail in this specification belong to the prior art known to those skilled in the art.
[0094] It should be noted that, in this article, relational terms such as first and second, etc. are only used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Moreover, the terms "include", "comprise" or any other variants thereof are intended to cover non-exclusive inclusion, so that a process, method, article or device including a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process, method, article or device.
[0095] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. A photosensitizer with high ROS generation efficiency and anti-tumor activity, characterized in that: The photosensitizer is prepared by coordinating bipyridine with metal iridium to synthesize a water-soluble bipyridine metal iridium complex.
2. A photosensitizer with high ROS generation efficiency and anti-tumor activity according to claim 1, characterized in that: The photosensitizer is synthesized by using a chlorophenylpyridine iridium complex as a matrix, modifying the matrix with 4,4'-dihydroxymethyl-2,2-bipyridine to synthesize Ir-OH. The specific synthesis method is as follows: S1. Dissolve the chlorophenylpyridine iridium complex and 4,4'-dihydroxymethyl-2,2-bipyridine in a mixed solution of dichloromethane and methanol, then gradually heat to 55°C in an oil bath and react for 12 hours; S2. After the reaction is completed, the mixture is naturally cooled to room temperature, and then an appropriate amount of ammonium hexafluorophosphate is added and stirred for half an hour. After cooling, the mixture is separated and purified by column chromatography to obtain a yellow solid, which is Ir-OH.
3. A photosensitizer with high ROS generation efficiency and anti-tumor activity according to claim 1, characterized in that: The volume ratio of the mixed solution of methyl chloride and methanol in step S1 is 1:
1.
4. The photosensitizer with high ROS generation efficiency and anti-tumor activity according to any one of claims 1 to 3 is used for tumor treatment by photodynamic therapy (PDT), characterized in that: Singlet oxygen 1 The generation efficiency of O2 and reactive oxygen species (ROS) is a key factor in evaluating the effect of PDT.
5. The photosensitizer with high ROS generation efficiency and anti-tumor activity according to claim 4 is used for tumor treatment by photodynamic therapy (PDT), characterized in that: According to the photosensitizer in vitro solution singlet oxygen 1 The efficiency of O2 and ROS production was used to preliminarily evaluate the feasibility of using photosensitizers in PDT. The specific operation is as follows: The photosensitizer Ir-OH was compared with the commercial photosensitizer dihydrochlorin e6 (Ce6), using 9,10-anthracenediyl-bis(methylenedicarboxylic acid) ABDA and 2,7-dichlorodihydrofluorescein diacetate DCFH as singlet oxygen. 1 The detection reagent of O2 and reactive oxygen species ROS, the test results show that within the range of 300s of light exposure, the photosensitizer Ir-OH exhibits a stronger singlet oxygen 1 The production rate of O2 and reactive oxygen species (ROS).
6. The photosensitizer Ir-OH with high ROS generation efficiency and anti-tumor activity according to any one of claims 1 to 3, characterized in that: Co-localization experiments confirmed that it was localized in lysosomes and that under light conditions, it could increase the concentration of reactive oxygen species (ROS) in tumor cells, causing lysosomal damage.
7. Use of the photosensitizer with high ROS production efficiency and anti-tumor activity according to any one of claims 1 to 3 at the cellular level.
8. The use of the photosensitizer with high ROS generation efficiency and anti-tumor activity according to any one of claims 1 to 3 in vivo, specifically manifested as: showing a good in vivo tumor inhibition effect on a 4T1 mouse tumor model in vivo, and having no obvious toxic side effects on mouse organ tissues.
Citation Information
Cited By
Method for semi-quantitatively detecting singlet oxygen by using 9, 10-anthracenediyl-di (methylene) dimalonic acid
CN120294213A
